Adenoviral vaccine platform

ReiThera offers its gorilla-derived adenovirus (GRAd) platform as a clinically validated viral vector technology for vaccine development.

GRAd is characterized by low seroprevalence in humans, supporting effective immune priming while limiting the impact of pre-existing anti-vector immunity. These properties make the platform well suited for heterologous prime–boost vaccination strategies, where GRAd can be combined with other adenoviral vectors or alternative vaccine platforms.

ReiThera contributes viral vector technology, manufacturing process development, and GMP production capabilities, covering the path from vector construction to clinical-grade supply. The company seeks collaboration with partners providing antigen design and antigen selection expertise, enabling complementary roles within the consortium.

The GRAd platform has been tested in clinical settings and is supported by scalable, GMP-compatible manufacturing processes, facilitating translation from preclinical development to clinical application.

As an SME technology and manufacturing partner, ReiThera can contribute through:

• GRAd vector engineering and vaccine construct development

• Process development, scale-up, and GMP manufacturing

• Analytical method development and quality control strategies

• Support for translational vaccine development programs

GRAd can be integrated in heterologous prime–boost regimens, including:

• adeno–adeno combinations (GRAd with a partner-selected adenoviral vector)

• adeno–MVA combinations (leveraging ReiThera’s MVA platform)

• adeno–RNA combinations (with RNA produced either by ReiThera or by project partners)

This offering is relevant for Horizon Europe projects focused on infectious diseases, preparedness, and next-generation vaccines, where clinically validated vectors and well-defined antigen concepts are required.

ReiThera aims to join collaborative consortia by providing its GRAd platform and industrial expertise, while partnering with organizations leading antigen discovery and design, without acting as project coordinator.